Zydus Lifesciences has entered exclusive negotiations to acquire a controlling stake in France-based medtech firm Amplitude Surgical SA for €256.8 million, the drugmaker said on Tuesday, as it ...

The project is expected to get underway in March 2025. Zydus Lifesciences on Tuesday said it will undertake development of a combination vaccine against shigellosis and typhoid. The company ...

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to ...

The proposed acquisition shall act as a platform to execute our global MedTech strategy and a natural extension for Zydus having a proven track record in life sciences and wellness segments ...

Zydus Lifesciences Limited on Tuesday announced that the company has entered into exclusive negotiations to acquire majority Amplitude Surgical. Purchase consideration amounts to €256.8mn for 85 ...

(Image Credits: Pixabay) Zydus on Wednesday said that a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients.

Zydus, a leading, discovery-based, global lifesciences company, announces the launch of ANVIMO (Letermovir), a breakthrough in the prevention of Cytomegalovirus (CMV) infection for haematopoietic ...